Walgreens Mulls Over Full Sale of VillageMD After a Whopping $6.2 Billion Investment

Walgreens is exploring the possibility of selling its entire stake in VillageMD, as revealed in the company's latest 8-K filing. This follows a substantial investment of $6.2 billion into the business, with $5.2 billion injected in 2021 alone. Initially aimed at expanding its network of physician offices, Walgreens is now assessing various strategic options.

Strategic Options Under Review

The company’s filing indicates that potential paths include a complete or partial sale of VillageMD, restructuring alternatives, or other strategic opportunities. Discussions are ongoing with VillageMD’s stakeholders and other interested parties regarding the future of this investment.

Financial Challenges Driving the Decision

Walgreens' shift in strategy is influenced by the significant ongoing and anticipated cash needs of VillageMD. This marks a notable departure from the company’s previous stance in June, where it expressed intentions to reduce but not entirely exit its stake in VillageMD. However, the financial strain, particularly VillageMD's unprofitability and default on a $2.3 billion credit facility provided by Walgreens, has prompted a reconsideration of its position.

Impact on Walgreens and VillageMD

Walgreens became the majority owner of VillageMD in 2021 to diversify its portfolio amid struggles in its core pharmacy business. Despite plans to operate 600 Village Medical clinics by next year, with a target of 1,000 by 2027, many clinics have already closed, contributing to a $6 billion net loss in Walgreens' March quarterly earnings. This decline in VillageMD's value has become a significant financial burden for the drugstore giant.